Data from Dual HER/VEGF Receptor Targeting Inhibits <i>In Vivo</i> Ovarian Cancer Tumor Growth
Marc A. Becker(Mayo Clinic), Paul Haluska(Mayo Clinic in Arizona), Kimberly R. Kalli(Mayo Clinic), James Krempski(University of North Carolina at Chapel Hill), Sean C. Harrington(Mayo Clinic), Tai W. Wong(Bristol-Myers Squibb (United States)), Thahir Farzan(Mayo Clinic), Xiaonan Hou(Mayo Clinic in Arizona), S. John Weroha
Cited by 0
Related Papers
Interferon-Regulatory Factor 4 Is Essential for the Developmental Program of T Helper 9 Cells
|Immunity|2010|539
Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer
|The Journal of Immunology|2011|250
Multi-omic profiling reveals widespread dysregulation of innate immunity and hematopoiesis in COVID-19
|The Journal of Experimental Medicine|2021|232
Tumor Development by Transgenic Expression of a Constitutively Active Insulin-Like Growth Factor I Receptor
|Cancer Research|2005|203
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
|Cancer Research|2017|169